StreetInsider.com News Articles

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals (Gilgamesh) against Enveric’s issued U.S. Patent No. 12,138,276 (the ’276 patent) has been withdrawn. This action follows Enveric’s filing of a Request for Discretionary Denial of the petition. As a result of this action, there are no remaining challenges currently pending against

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Wed, 25 Feb 2026 08:00:00 -0500

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

Enveric Biosciences reports new data on EB-003 receptor signaling

Thu, 19 Feb 2026 08:01:20 -0500

Enveric Biosciences (NASDAQ: ENVB) announced new data showing its lead drug candidate EB-003 activates both Gq- and β-arrestin signaling pathways at the 5-HT₂A receptor, according to a company statement.

The biotechnology company generated the data using proprietary bioluminescence resonance energy transfer (BRET) assays. Enveric developed these assays internally because commercial assays for measuring pathway-specific 5-HT₂A signaling were not available, the company said.

The data indicate EB-003 shows a modest preference toward β-arrestin over Gq signaling relative to serotonin, the receptor's native ligand. Both pathways appear engaged at biologically relevant levels, according to the company.

The announcement references a recent study published in Nature

Enveric Biosciences reports new data on EB-003 receptor signaling

Thu, 19 Feb 2026 08:01:20 -0500

The announcement references a recent study published in Nature

Enveric Biosciences reports new data on EB-003 receptor signaling

Thu, 19 Feb 2026 08:01:20 -0500

The announcement references a recent study published in Nature

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Thu, 19 Feb 2026 08:00:00 -0500

Proprietary assays demonstrate dual Gq and β-arrestin signaling at 5-HT₂A, pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects

A recent independent Nature study reports that distinct signaling pathways support mechanistic separation of therapeutic benefit from hallucinations

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. Multiple independent, peer-reviewed studies have previously shown that selective activation of 5-HT₂A

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Thu, 19 Feb 2026 08:00:00 -0500

Proprietary assays demonstrate dual Gq and β-arrestin signaling at 5-HT₂A, pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects

A recent independent Nature study reports that distinct signaling pathways support mechanistic separation of therapeutic benefit from hallucinations

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. Multiple independent, peer-reviewed studies have previously shown that selective activation of 5-HT₂A